Medtronic, Inc. Receives FDA Approval for New Tripolar, 16-Electrode Neurostimulation Lead to Treat Chronic Pain

MINNEAPOLIS--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT), today announced that the U.S. Food and Drug Administration (FDA) has granted pre-market approval (PMA) to its new Specify™ 5-6-5 surgical lead for neurostimulation therapy, a safe and effective treatment for chronic pain that uses the company’s extensive line of implantable neurostimulation systems, including the RestoreADVANCED® and PrimeADVANCED® neurostimulators.
MORE ON THIS TOPIC